Compare WTTR & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WTTR | ADPT |
|---|---|---|
| Founded | 2016 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.7B |
| IPO Year | 2017 | 2019 |
| Metric | WTTR | ADPT |
|---|---|---|
| Price | $20.17 | $22.27 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | $16.67 | ★ $17.78 |
| AVG Volume (30 Days) | 1.8M | ★ 2.9M |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.65% | N/A |
| EPS Growth | N/A | ★ 63.89 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,528,930,000.00 | $276,976,000.00 |
| Revenue This Year | $2.11 | $3.98 |
| Revenue Next Year | $4.94 | $22.72 |
| P/E Ratio | $69.16 | ★ N/A |
| Revenue Growth | ★ 120.79 | 54.77 |
| 52 Week Low | $7.86 | $9.96 |
| 52 Week High | $21.67 | $23.15 |
| Indicator | WTTR | ADPT |
|---|---|---|
| Relative Strength Index (RSI) | 55.36 | 60.64 |
| Support Level | $17.60 | $15.08 |
| Resistance Level | $20.27 | $22.97 |
| Average True Range (ATR) | 0.80 | 1.25 |
| MACD | 0.08 | -0.14 |
| Stochastic Oscillator | 60.21 | 77.51 |
Select Water Solutions Inc provides sustainable water-management solutions to the energy industry in the United States. These solutions are supported by the company's critical water infrastructure assets, chemical manufacturing, and water treatment and recycling capabilities. The company's reportable segments are Water Services, Water Infrastructure, and Chemical Technologies. It generates maximum revenue from the Water Services segment, which comprises its short-cycle, field-based service offerings, including water transfer, water sourcing, fluids hauling, monitoring, containment, water-network automation, and the services associated with Peak Rentals. This segment earns revenue via market-based day rates, time-and-materials, or per-barrel delivered under MSAs and short-term work orders.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.